JPWO2019173693A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019173693A5 JPWO2019173693A5 JP2020571330A JP2020571330A JPWO2019173693A5 JP WO2019173693 A5 JPWO2019173693 A5 JP WO2019173693A5 JP 2020571330 A JP2020571330 A JP 2020571330A JP 2020571330 A JP2020571330 A JP 2020571330A JP WO2019173693 A5 JPWO2019173693 A5 JP WO2019173693A5
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- domain
- nucleic acid
- recombinant nucleic
- subunit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091008874 T cell receptors Proteins 0.000 claims description 142
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 132
- 150000007523 nucleic acids Chemical class 0.000 claims description 117
- 108020004707 nucleic acids Proteins 0.000 claims description 115
- 102000039446 nucleic acids Human genes 0.000 claims description 115
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 31
- 239000012634 fragment Substances 0.000 claims description 23
- 239000003446 ligand Substances 0.000 claims description 23
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 22
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 101710163270 Nuclease Proteins 0.000 claims description 12
- 230000004048 modification Effects 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000003834 intracellular effect Effects 0.000 claims description 9
- 230000004068 intracellular signaling Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 230000011664 signaling Effects 0.000 claims description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 239000012636 effector Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002463 transducing effect Effects 0.000 claims description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 2
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 claims description 2
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 claims description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 108091033409 CRISPR Proteins 0.000 claims description 2
- 238000010354 CRISPR gene editing Methods 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102100025096 Mesothelin Human genes 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 230000011748 cell maturation Effects 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000018883 protein targeting Effects 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 9
- 108010073807 IgG Receptors Proteins 0.000 description 6
- 102000009490 IgG Receptors Human genes 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- -1 CD86 Proteins 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 2
- 101001132524 Homo sapiens Retinoic acid early transcript 1E Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 2
- 108010073816 IgE Receptors Proteins 0.000 description 2
- 102000009438 IgE Receptors Human genes 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 102100033964 Retinoic acid early transcript 1E Human genes 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 108010065816 zeta chain antigen T cell receptor Proteins 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000607316 Homo sapiens UL-16 binding protein 5 Proteins 0.000 description 1
- 101000607306 Homo sapiens UL16-binding protein 1 Proteins 0.000 description 1
- 101000607320 Homo sapiens UL16-binding protein 2 Proteins 0.000 description 1
- 101000607318 Homo sapiens UL16-binding protein 3 Proteins 0.000 description 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100040010 UL-16 binding protein 5 Human genes 0.000 description 1
- 102100040012 UL16-binding protein 1 Human genes 0.000 description 1
- 102100039989 UL16-binding protein 2 Human genes 0.000 description 1
- 102100040011 UL16-binding protein 3 Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003515 double negative t cell Anatomy 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 210000004318 naive thymus-derived CD4-positive, alpha-beta T lymphocyte Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862641159P | 2018-03-09 | 2018-03-09 | |
| US62/641,159 | 2018-03-09 | ||
| PCT/US2019/021315 WO2019173693A1 (en) | 2018-03-09 | 2019-03-08 | Compositions and methods for tcr reprogramming using fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021515598A JP2021515598A (ja) | 2021-06-24 |
| JPWO2019173693A5 true JPWO2019173693A5 (enrdf_load_stackoverflow) | 2022-03-16 |
Family
ID=67846339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020571330A Withdrawn JP2021515598A (ja) | 2018-03-09 | 2019-03-08 | 融合タンパク質を用いたｔｃｒリプログラミングのための組成物及び方法 |
Country Status (12)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US11242376B2 (en) | 2016-08-02 | 2022-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| AU2017341048A1 (en) | 2016-10-07 | 2019-05-23 | TCR2 Therapeutics Inc. | Compositions and methods for T-cell receptors reprogramming using fusion proteins |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| WO2020210398A1 (en) * | 2019-04-11 | 2020-10-15 | Fate Therapeutics, Inc. | CD3 RECONSTITUTION IN ENGINEERED iPSC AND IMMUNE EFFECTOR CELLS |
| WO2021035170A1 (en) * | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| AU2020344628A1 (en) * | 2019-09-12 | 2022-04-07 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| CN115052973B (zh) * | 2019-11-06 | 2025-07-01 | 贝勒医学院 | 用于产生细胞毒性效应子记忆t细胞以用于癌症的t细胞治疗的方法 |
| WO2021133959A2 (en) * | 2019-12-24 | 2021-07-01 | TCR2 Therapeutics Inc. | Compositions and methods for gamma delta tcr reprogramming using fusion proteins |
| EP4196498A1 (en) * | 2020-08-12 | 2023-06-21 | Migal Galilee Research Institute Ltd. | Alloreactive immune cell-distancing device and uses thereof for protecting donor-derived cells from allorejection |
| AU2021410788A1 (en) * | 2020-12-23 | 2023-08-03 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN117480247A (zh) * | 2021-04-15 | 2024-01-30 | 恺兴生命科技(上海)有限公司 | 嵌合t细胞受体及其应用 |
| WO2023179795A1 (zh) * | 2022-03-25 | 2023-09-28 | 立凌生物制药(苏州)有限公司 | 一种快速且简便地获得正确配对tcr的方法以及获得的tcr |
| CN119487071A (zh) * | 2022-06-24 | 2025-02-18 | 北京可瑞生物科技有限公司 | 基于t细胞受体的双特异性多肽分子及其用途 |
| IL321647A (en) * | 2022-12-23 | 2025-08-01 | Tcrcure Biopharma Corp | Engineered T-cell receptors and engineered immune cells expressing the same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003208839A1 (en) * | 2002-02-13 | 2003-09-04 | Micromet Ag | De-immunized (poly)peptide constructs |
| US9181527B2 (en) * | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| UA118652C2 (uk) * | 2012-05-25 | 2019-02-25 | Селлектіс | Спосіб конструювання неалореактивної і стійкої до імуносупресії т-клітини для імунотерапії |
| EP3466967A1 (en) * | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| PT3468997T (pt) * | 2016-06-08 | 2023-12-07 | Debra Zack | Tratamento de doenças relacionadas com igg4 com anticorpos anti-cd19 com ligação cruzada a cd32b |
| CN110177803A (zh) * | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| CA3047999A1 (en) * | 2016-12-21 | 2018-06-28 | TCR2 Therapeutics Inc. | Engineered t cells for the treatment of cancer |
-
2019
- 2019-03-08 SG SG11202008721SA patent/SG11202008721SA/en unknown
- 2019-03-08 EP EP19763494.2A patent/EP3765039A4/en not_active Withdrawn
- 2019-03-08 WO PCT/US2019/021315 patent/WO2019173693A1/en unknown
- 2019-03-08 BR BR112020018173-0A patent/BR112020018173A2/pt not_active IP Right Cessation
- 2019-03-08 US US16/979,380 patent/US20210361704A1/en not_active Abandoned
- 2019-03-08 CN CN201980023038.1A patent/CN111954714A/zh active Pending
- 2019-03-08 JP JP2020571330A patent/JP2021515598A/ja not_active Withdrawn
- 2019-03-08 KR KR1020207028766A patent/KR20200130383A/ko not_active Abandoned
- 2019-03-08 MX MX2020009371A patent/MX2020009371A/es unknown
- 2019-03-08 CA CA3093449A patent/CA3093449A1/en active Pending
- 2019-03-08 AU AU2019231792A patent/AU2019231792A1/en not_active Abandoned
- 2019-03-08 EA EA202092093A patent/EA202092093A1/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11008376B2 (en) | Trifunctional T cell-antigen coupler and methods and uses thereof | |
| US11472884B2 (en) | Humanized BCMA antibody and BCMA-CAR-T cells | |
| JPWO2019173693A5 (enrdf_load_stackoverflow) | ||
| JP7636650B2 (ja) | 二量体形成剤調節性免疫受容体複合体 | |
| CN111954714A (zh) | 使用融合蛋白进行tcr重编程的组合物和方法 | |
| WO2017112784A1 (en) | Spycatcher and spytag: universal immune receptors for t cells | |
| CN113045657B (zh) | 一种人源化抗人bcma单克隆抗体及其car-t细胞 | |
| US20220133792A1 (en) | Signaling platforms for chimeric antigen receptor t cells | |
| WO2021188454A1 (en) | Engineered cell compositions and methods of use thereof | |
| WO2022232277A1 (en) | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS AND TGFβR SWITCH | |
| JP2022548866A (ja) | 融合タンパク質を用いたｔｃｒリプログラミングのための組成物及び方法 | |
| JPWO2021050948A5 (enrdf_load_stackoverflow) | ||
| WO2025117851A1 (en) | Meso-fap with adam17 inhibitor or itk inhibitor | |
| Bridgeman et al. | T-Bodies: Antibody-Based Engineered T-Cell Receptors | |
| Torikai et al. | Engineering T Cells to target tumor cells | |
| HK40032892A (en) | Humanized bcma antibody and bcma-car-t cells | |
| JPWO2022222905A5 (enrdf_load_stackoverflow) | ||
| JPWO2020185121A5 (enrdf_load_stackoverflow) |